Fig. 3: Pseudovirus neutralization ID50 titers by time point and variant in a subset (n = 22–23) of participants who were uninfected. | Nature Medicine

Fig. 3: Pseudovirus neutralization ID50 titers by time point and variant in a subset (n = 22–23) of participants who were uninfected.

From: Comparison of bivalent and monovalent SARS-CoV-2 variant vaccines: the phase 2 randomized open-label COVAIL trial

Fig. 3

Time points were days 1, 15 and 91. Variants were D614G and Omicron BA.1, BA.2.12.1, BA.4/BA.5, BA.2.75, BA.4.6, BF.7, BA.2.75.2, BQ.1.1 and XBB.1. a, Stage 1 mRNA-1273 prototype monovalent vaccine. b, Stage 1 mRNA-1273 Omicron BA.1 + prototype bivalent vaccine. In a and b, boxes and horizontal bars denote interquartile range and median ID50, respectively; whiskers denote 95% CI; and n represents the number of samples tested. c,d, Radar plots of the pseudovirus neutralization GMTs at day 15 (c) and day 91 (d) for the two vaccine arms in stage 1 mRNA-1273 prototype monovalent vaccine (red) and mRNA-1273 Omicron BA.1 + prototype bivalent vaccine (blue). Circles are GMT estimates for each variant. In the radar plots, each variant is represented by its own vertical line or spoke, and the spokes are evenly distributed around the circle. Each horizontal line along a vertical spoke represents the GMT at a ten-fold dilution, with the value closest to the center being 1 and farthest from the center being 10,000 or 104. A line is drawn connecting the GMT data values for vaccine arm at the individual variants represented by its vertical spoke.

Back to article page